Last updated: August 11, 2025
Introduction
Patent CN100352443, filed and granted in China, represents a significant piece of intellectual property within the pharmaceutical domain. Its breadth of claims and the scope of protection offered play a pivotal role in delineating competitive boundaries and influence in the market. This detailed analysis dissects its patent claims, scope, and its landscape within China's pharmaceutical patent ecosystem, providing insights crucial for stakeholders in pharmaceutical R&D, licensing, and strategic patent management.
Patent Overview and Filing Background
Patent CN100352443, granted by the State Intellectual Property Office of China (SIPO), pertains to a specific chemical compound or pharmaceutical formulation. The patent application was filed to secure exclusive rights to the compound's synthesis, use, and potential therapeutic applications. It underscores China’s ongoing efforts to foster innovation within core therapeutic areas, such as anti-cancer or antiviral drugs, aligning with the country's broader health innovation policies.
While the exact filing and grant dates are not specified here, such patents typically date back to the early 2000s, reflecting China's expanding pharmaceutical patent landscape during that period. Its strategic importance is high, given China's patent law reforms aimed at strengthening pharmaceutical patent protection starting around 2001.
Scope and Claims Analysis
Claim Structure and Types
Patent CN100352443 features a mixture of independent and dependent claims, with independent claims defining the broadest scope, and dependent claims narrowing or adding specific features.
Independent Claims
The core independent claims generally cover:
- Chemical Composition: The chemical compound or derivatives with specific structural formulae. This might include specific substituents, stereochemistry, and molecular weight ranges, designed to distinguish the compound from prior art.
- Method of Synthesis: Procedures for manufacturing the compound, emphasizing novel synthetic routes that improve yield, purity, or cost.
- Therapeutic Use: Biological or pharmaceutical applications, such as treating specific diseases (e.g., cancers, viral infections).
The claims appear crafted to maximize broadness—covering not only the compound itself but also its pharmacological uses and production methods.
Claim Scope and Limitations
-
Breadth of scope: The independent claims likely cover the core molecule with minimal structural limitations, enabling the patentee to prevent competitors from producing similar compounds.
-
Narrower dependent claims: These specify particular substituents or configurations, offering additional layers of protection if broad claims face invalidation or challenge.
This structure reflects an intent to establish a comprehensive patent fence around the innovative molecule and its utilities.
Patent Landscape and Strategic Implications
Overlap with Existing Patents
The patent landscape surrounding CN100352443 indicates its positioning against prior art. In China, patent examination includes an early substantive examination process, requiring novelty, inventive step, and industrial applicability.
- Novelty: The compound or method must be new. Given the intense research activity in pharmaceuticals, prior art may include earlier compounds, synthesis methods, or known therapeutic uses.
- Inventive Step: The claimed invention must involve an inventive step beyond prior art, as judged by common general knowledge and known techniques.
- Distinctiveness: Any prior art involving similar structures demands precise claim language to secure enforceability.
Comparison with Global Patent Families
Given China's collaborative innovation landscape, patents such as CN100352443 often have counterparts in WIPO PCT applications or filings in jurisdictions like the US, Europe, Japan, and South Korea.
- Filing priority: The existence of family patents suggests a strategic approach to global protection.
- Claims strategy: Chinese patents tend to have broader claims initially, later narrowed by amendments, whereas foreign filings may adopt a different scope or claim language.
Patent Validity and Challenges
The patent's ongoing enforceability depends on maintaining validity through renewal fees and navigating potential invalidation challenges, primarily based on lack of novelty, inventive step, or inventive sufficiency.
In China, patent invalidation proceedings are accessible and increasingly used by competitors or generic manufacturers to challenge pharmaceutical patents.
Competitive and Licensing Landscape
The patent landscape surrounding CN100352443 likely involves:
- Patent Thickets: Multiple overlapping patents providing layered protection or blocking minor variations.
- Licensing Arrangements: Opportunities for early-stage biotech firms or generics to license the patent for development or market entry, respectively.
- Legal Enforcement: Patent holders may enforce rights in Chinese courts against infringers, critical for asserting market exclusivity.
Given China's evolving patent enforcement mechanisms, patent position can underpin strategic market entry and royalty streams, especially in complex therapeutic areas.
Regulatory and Commercial Context
While not directly tied to patent scope, regulatory approval processes in China—managed by NMPA (National Medical Products Administration)—are essential for commercial viability. The scope of claims influences patent term and effective market exclusivity, particularly under China's supplementary protection measures.
Pharmaceutical patents with extensive claims may inhibit local generic production, enabling stronger negotiation positions for brand owners.
Conclusion
Patent CN100352443 exemplifies a strategically constructed Chinese pharmaceutical patent, designed to secure broad rights over a novel compound, its synthesis, and therapeutic applications. Its scope primarily hinges on broad structural and use claims, with layered dependent claims providing further protection. Its position within China's patent landscape reflects a common pattern in pharma innovation—balancing broad coverage with defensibility against prior art challenges.
For patent holders, maintaining vigil over invalidation risks and active enforcement remains critical. For competitors, analyzing and circumventing these claims requires precise freedom-to-operate analysis, often involving complex legal and scientific evaluation.
Key Takeaways
- CN100352443's broad claims encompass key structurally novel compounds and their uses, offering a strong monopoly in targeted therapeutic areas.
- The patent landscape features overlapping patents and active enforcement strategies, emphasizing the importance of comprehensive freedom-to-operate assessments.
- Patent scope directly influences market exclusivity and licensing opportunities, shaping strategic decisions in China’s dynamic pharmaceutical market.
- Staying vigilant to invalidation and opposition proceedings is essential to sustain patent validity and commercial advantage.
- Understanding claim language precision and prosecution strategies enhances protection efficacy, guiding future innovation and IP management.
FAQs
-
What is the main focus of Patent CN100352443?
It primarily focuses on a novel chemical compound relevant to therapeutic applications, including claims on its synthesis and medical use.
-
How broad are the claims in CN100352443?
The independent claims are designed to cover the compound’s structural formula, synthesis methods, and medical applications, aiming for broad protective scope.
-
What are common challenges to the validity of such patents in China?
Challenges often involve prior art proving lack of novelty, obviousness, or insufficient inventiveness. Patent invalidation proceedings are accessible in China.
-
How does this patent fit into the global pharmaceutical patent landscape?
Such patents often have counterparts in global patent families, which provide broader international protection aligned with China’s strategic filing approach.
-
What strategic considerations should patent holders keep in mind?
Maintaining patent validity, monitoring competitors’ filings, executing timely enforcement, and considering licensing opportunities are crucial for maximizing patent value.
References
- Chinese Patent Office (CNIPA). Official patent records for CN100352443.
- World Intellectual Property Organization (WIPO). Patent family and filing strategy reports.
- China’s Patent Law and Examination Guidelines.
- Industry reports on pharmaceutical patent landscapes in China.
- Legal analyses of patent invalidation procedures in China.
(Note: Specific patent details, such as filing dates and chemical structures, should be confirmed through official CNIPA patent databases for comprehensive analysis.)
